Management of hepatic sarcoidosis

• Verfasst von: Sollors, Janina [VerfasserIn]
• Verfasst von: Schlevogt, Bernhard [VerfasserIn]
• Verfasst von: Schmidt, Hartmut J. [VerfasserIn]
• Verfasst von: Wörns, Marcus-Alexander [VerfasserIn]
• Verfasst von: Galle, Peter R. [VerfasserIn]
• Verfasst von: Qian, Yuquan [VerfasserIn]
• Verfasst von: Antoni, Christoph Helmer [VerfasserIn]
• Verfasst von: Weis, Cleo-Aron Thias [VerfasserIn]
• Verfasst von: Hetjens, Svetlana [VerfasserIn]
• Verfasst von: Bergner, Raoul [VerfasserIn]
• Verfasst von: Ebert, Matthias [VerfasserIn]
• Verfasst von: Teufel, Andreas [VerfasserIn]
• Titel: Management of hepatic sarcoidosis
• Verf.angabe: Janina Sollors, Bernhard Schlevogt, Hartmut J. Schmidt, Marcus Wörns, Peter R. Galle, Yuquan Qian, Christoph Antoni, Cleo-Aron Weis, Svetlana Hetjens, Raoul Bergner, Matthias P. Ebert, Andreas Teufel
• E-Jahr: 2022
• Jahr: 15 Sep. 2022
• Umfang: 8 S.
• Fussnoten: Gesehen am 18.01.2023
• Titel Quelle: Enthalten in: Journal of gastrointestinal and liver diseases
• Ort Quelle: Cluj-Napoca : Soc., 2006
• Jahr Quelle: 2022
• Band/Heft Quelle: 31(2022), 3, Seite 323-330
• ISSN Quelle: 1842-1121
• DOI: doi:10.15403/jgld-4122
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: diagnosis
• Sach-SW: hepatic sarcoidosis
• Sach-SW: liver
• Sach-SW: sarcoidosis
• Sach-SW: treatment
• K10plus-PPN: 1831400863

Abstract

Background and Aims: Liver involvement in sarcoidosis may occur in up to 60% of all patients. As many patients experience only minor symptoms, a high number of undiagnosed cases must be assumed. In order to successfully identify patients with hepatic sarcoidosis, a throughout characterization of these patients and their course of disease is necessary. - Methods: We collected 40 patients from four German centers to evaluate current treatment standards and course of disease. All of our patients underwent liver biopsy with histologically proven granulomatous hepatitis. - Results: Detailed characterization of our patients showed an overall benign course of disease. Treatment was very diverse with glucocorticoids for 1 year in 55% (22/40), 5-10 years in 18% (7/40), and permanently in 18% (7/40). Other treatments included disease-modifying anti-rheumatic drugs (DMARDs), the conventional non-biological type in 53% of all patients (of these 81% received azathioprine, 46% metotrexate, 10% hydroxychloroquine, 10% mycophenolate mofetil and 10% cyclophosphamide and biologicals in 8%. Despite these very diverse treatments, patients generally showed slow progression of the disease. Two patients died. None of our patients received a liver transplantation. - Conclusions: Patients received diverse treatments and generally showed slow progression of the disease. Based on our experience, we proposed a diagnostic work up and surveillance strategy as a basis for future, prospective register studies.